DK1792610T3 - Terapeutiske bioadhæsive systemet med langvarig frigivelse - Google Patents

Terapeutiske bioadhæsive systemet med langvarig frigivelse

Info

Publication number
DK1792610T3
DK1792610T3 DK07006150T DK07006150T DK1792610T3 DK 1792610 T3 DK1792610 T3 DK 1792610T3 DK 07006150 T DK07006150 T DK 07006150T DK 07006150 T DK07006150 T DK 07006150T DK 1792610 T3 DK1792610 T3 DK 1792610T3
Authority
DK
Denmark
Prior art keywords
long
therapeutic
term release
bioadhesive system
therapeutic bioadhesive
Prior art date
Application number
DK07006150T
Other languages
Danish (da)
English (en)
Inventor
Jean-Marc Aiache
Dominique Constantini
Christine Chaumont
Original Assignee
Bioalliance Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma filed Critical Bioalliance Pharma
Application granted granted Critical
Publication of DK1792610T3 publication Critical patent/DK1792610T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK07006150T 2001-07-23 2002-07-23 Terapeutiske bioadhæsive systemet med langvarig frigivelse DK1792610T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0109811A FR2827517B1 (fr) 2001-07-23 2001-07-23 Systemes therapeutiques bioadhesifs a liberation prolongee
PCT/FR2002/002635 WO2003009800A1 (fr) 2001-07-23 2002-07-23 Systemes therapeutiques bioadhesifs a liberation prolongee

Publications (1)

Publication Number Publication Date
DK1792610T3 true DK1792610T3 (da) 2009-02-16

Family

ID=8865807

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02774826T DK1408911T3 (da) 2001-07-23 2002-07-23 Terapeutiske bioadhæsive systemer med forhalet frigivelse
DK07006150T DK1792610T3 (da) 2001-07-23 2002-07-23 Terapeutiske bioadhæsive systemet med langvarig frigivelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02774826T DK1408911T3 (da) 2001-07-23 2002-07-23 Terapeutiske bioadhæsive systemer med forhalet frigivelse

Country Status (15)

Country Link
US (5) US6916485B2 (zh)
EP (2) EP1408911B1 (zh)
JP (2) JP4657603B2 (zh)
CN (2) CN1547464B (zh)
AT (2) ATE411003T1 (zh)
CA (1) CA2455633C (zh)
CY (2) CY1107828T1 (zh)
DE (2) DE60229456D1 (zh)
DK (2) DK1408911T3 (zh)
ES (2) ES2316108T3 (zh)
FR (1) FR2827517B1 (zh)
HK (1) HK1107516A1 (zh)
IL (2) IL159842A0 (zh)
PT (2) PT1408911E (zh)
WO (1) WO2003009800A1 (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
EP1508329A1 (en) * 2003-08-20 2005-02-23 Matsumoto Dental University Composition for an antifungal agent for suppressing fungal growth in an oral cavity
JP2005097271A (ja) * 2003-08-20 2005-04-14 Matsumoto Shika Univ 抗真菌剤用組成物
CN1302764C (zh) * 2005-01-10 2007-03-07 凌沛学 一种妇科用药阴道凝胶片
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
EP1837020A1 (en) * 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
EP1972332A1 (en) * 2007-03-23 2008-09-24 BioAlliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
ES2626131T3 (es) 2007-10-17 2017-07-24 Laboratoire Hra Pharma Antagonistas del receptor de glucocorticoides tales como mifepristona para tratar el síndrome de Cushing
CA2704946C (en) 2007-11-13 2013-09-24 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CA2774149A1 (en) 2009-09-15 2011-03-24 Cemag Lubiprostone for obstetrical or gynecological applications
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
CA2782779C (en) * 2009-12-09 2015-07-14 Bioalliance Pharma Mucoadhesive buccal tablets for the treatment of orofacial herpes
EP2335690A1 (en) * 2009-12-09 2011-06-22 BioAlliance Pharma Mucoadhesive buccal tablets for the treatment of orofacial herpes
US8592434B2 (en) * 2009-12-09 2013-11-26 Bioalliance Pharma Sa Mucoadhesive buccal tablets for the treatment of orofacial herpes
US8962603B2 (en) 2010-02-01 2015-02-24 Laboratoire Hra-Pharma Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
WO2011091892A1 (en) 2010-02-01 2011-08-04 Ulmann Andre A method for late post coital contraception using ulipristal acetate
CN101822701B (zh) * 2010-06-08 2012-11-21 格特生物制药（天津）有限公司 一种治疗畜禽痢疾、肠炎的杨树花缓释片及其制备方法
FR2967575A1 (fr) * 2010-11-19 2012-05-25 Df3 Composition et formulation galenique bio-adhesive
EP2815747B8 (en) * 2012-02-14 2018-06-27 Kyukyu Pharmaceutical Co., Ltd. Intraoral soluble-type film preparation
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
MY181448A (en) 2013-04-10 2020-12-22 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
AU2014407862B2 (en) 2014-09-29 2020-03-26 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
JP6679616B2 (ja) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 炎症及び疼痛の治療のための組成物及び方法
EP3554489A4 (en) 2016-12-15 2020-06-17 Evoke Pharma, Inc. TREATMENT OF MODERATE AND SERIOUS GASTROPARESIS
DE102019000321A1 (de) 2019-01-14 2020-07-16 Beuth Hochschule Für Technik Berlin Orale Polymerzusammensetzung mit verzögerter Freisetzung
DE102019000322A1 (de) 2019-01-14 2020-07-16 Beuth Hochschule Für Technik Berlin Polymerzusammensetzung mit antiseptischen Eigenschaften und Verfahren zur Herstellung
CN110237042A (zh) * 2019-06-04 2019-09-17 华润双鹤利民药业（济南）有限公司 硝酸咪康唑阴道片生产工艺
EP4009968A4 (en) * 2019-08-09 2023-08-16 The Board Of Trustees Of The University Of Illinois COMBINED TREATMENT OF SYSTEMIC FUNGAL INFECTIONS
FR3110079A1 (fr) * 2020-05-12 2021-11-19 Vectans Pharma Comprimé mucoadhésif pour le traitement des infections fongiques oropharyngées
DE102020007979A1 (de) 2020-12-29 2022-06-30 Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58210007A (ja) 1982-06-02 1983-12-07 Takeda Chem Ind Ltd 上部「あ」
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US4849229A (en) 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
DE3433239A1 (de) * 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4915948A (en) * 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5330746A (en) * 1988-05-03 1994-07-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dental varnish composition, and method of use
US5160737A (en) 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
US5116603A (en) * 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
US4951948A (en) * 1989-04-17 1990-08-28 Peng Jung C Shock absorbing bat
FR2665357B1 (fr) * 1990-07-31 1995-03-31 Aiache Jean Marc Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee.
GB9318641D0 (en) * 1993-09-08 1993-10-27 Edko Trading Representation Compositions
JP4137179B2 (ja) * 1994-03-30 2008-08-20 ジーエス ディベロップメント エービー 生物付着性物質としての脂肪酸エステルの使用
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
DE69615704T2 (de) * 1995-12-27 2002-07-11 Janssen Pharmaceutica Nv Bioadhesive feste arzneimittelform
AU6853498A (en) 1997-04-22 1998-11-13 Nippon Kayaku Kabushiki Kaisha Flutamide preparations and method for manufacturing the same
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
GB9826192D0 (en) * 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee

Also Published As

Publication number Publication date
EP1792610A3 (fr) 2007-06-27
DK1408911T3 (da) 2008-01-28
US20070160668A1 (en) 2007-07-12
EP1408911A1 (fr) 2004-04-21
EP1408911B1 (fr) 2007-09-19
DE60229456D1 (de) 2008-11-27
WO2003009800A1 (fr) 2003-02-06
PT1408911E (pt) 2007-12-26
HK1107516A1 (en) 2008-04-11
US20110039800A1 (en) 2011-02-17
DE60222557D1 (de) 2007-10-31
ATE411003T1 (de) 2008-10-15
IL159842A0 (en) 2004-06-20
ES2316108T3 (es) 2009-04-01
JP2010270142A (ja) 2010-12-02
US20030108603A1 (en) 2003-06-12
FR2827517B1 (fr) 2003-10-24
EP1792610B1 (fr) 2008-10-15
DE60222557T2 (de) 2008-06-19
EP1792610A2 (fr) 2007-06-06
CN1547464A (zh) 2004-11-17
FR2827517A1 (fr) 2003-01-24
JP4657603B2 (ja) 2011-03-23
CY1108796T1 (el) 2014-04-09
US20050208129A1 (en) 2005-09-22
US7651698B2 (en) 2010-01-26
CA2455633C (fr) 2012-05-01
ATE373464T1 (de) 2007-10-15
CN1547464B (zh) 2011-02-09
US20130310335A1 (en) 2013-11-21
CN101524337A (zh) 2009-09-09
US6916485B2 (en) 2005-07-12
CA2455633A1 (fr) 2003-02-06
IL159842A (en) 2010-02-17
JP2004537558A (ja) 2004-12-16
CY1107828T1 (el) 2013-06-19
US8518442B2 (en) 2013-08-27
PT1792610E (pt) 2009-01-12
ES2294170T3 (es) 2008-04-01

Similar Documents

Publication Publication Date Title
DK1792610T3 (da) Terapeutiske bioadhæsive systemet med langvarig frigivelse
ES2082723B1 (es) Formulacion farmaceutica de fluoxetina en forma dispersable.
NO2016024I1 (no) Farmasøytisk blanding eller assosisjon som inneholder som aktive ingredienser: (1) ceftazidim eller et salt derav, og (2) avibaktam eller et farmasøytisk akseptabelt salt derav
MXPA03011947A (es) Formulaciones de olopatidina para administracion topica.
BR0112962A (pt) Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
NO994431L (no) Ny formulering
BR9506956A (pt) Composição farmacêutica antitussígena
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
RS49520B (sr) Antimikrobno aktivne smeše
CO5251413A1 (es) Uso nuevo
NZ521515A (en) Composition comprising paracetamol and niflumic acid
JO2370B1 (en) Pharmaceutical formulations for the treatment of painful, inflamed and ulcerated conditions of wet epithelial surfaces such as mucositis, stomatitis and Behçet syndrome
UA40515A (uk) Горілка "столітня"